We bring deep expertise and passion to our work addressing numerous health challenges around the world. In 2012, 79% of volunteering done by U.S.-based employees utilized their professional skills and expertise.
AbbVie is committed to addressing and solving the world's recognized health challenges, including neglected tropical diseases (NTDs). NTDs are a group of infections that disproportionately impact the world's poor and marginalized populations. According to the World Health Organization (WHO), more than 1 billion people – one-sixth of the global population – suffer from one or more of these conditions, including onchocerciasis (river blindness), lymphatic filariasis (elephantiasis), Chagas disease, helminth infections and sleeping sickness.
Many developing countries lack the necessary infrastructure to monitor the spread of NTDs and related conditions such as malaria and tuberculosis. Some of these diseases have not been fully studied and many are not easily treated with existing medicines.
The Executive Council on Neglected Diseases coordinates efforts across the company to contribute innovative technologies, compounds for screening, and our scientific expertise. In 2012, more than 100 of AbbVie’s most experienced scientists contributed their expertise to helping solve NTDs through drug development projects, advisory boards and compound screening partner organizations. We have provided a large library of diverse chemicals to screen against many NTDs, collaborating with the following partners: